02008naa a2200277 a 450000100080000000500110000800800410001902400520006010000220011224501700013426000090030452011280031365000170144165000140145865300290147265300190150165300180152065300190153865300290155770000190158670000140160570000220161970000130164170000210165477300550167521436482022-06-02       2022    bl uuuu     u00u1 u    #d7 ahttps://doi.org/10.1007/s00203-022-02787-z2DOI1 aSANTOS, E. M. dos  aNanoencapsulated Lippia rotundifolia antimicrobial peptidebsynthesis, characterization, antimicrobial activity, and cytotoxicity evaluations.h[electronic resource]  c2022  aAntimicrobial peptides (AMP) are promising novel antibiotics but exhibit low stability and can be toxic. The AMP encapsulation can be used to protect the drug and control its release rates. The Lr-AMP1f encapsulated into chitosan nanoparticle (NP) by ionic gelation method reached 90% efficiency. The results indicated that the hydrodynamic particle size of NPs increased from 196.1 ± 3.14 nm (free NP) to 228.1 ± 12.22 nm (nanoencapsulated Lr-AMP1f), while the atomic force microscope showed the spherical shape. The Zeta potential of the nanoencapsulated Lr-AMP1f was high (+ 35 mV). These AMP-loaded NPs exhibited stability for up to 21 days of storage. The minimum inhibitory concentration (MIC) of free Lr-AMP1f was 8 µg/mL for E. coli and S. epidermidis. However, the nanoencapsulated Lr-AMP1f produced a bacteriostatic effect against both bacteria at 8 µg/mL. The MIC of nanoencapsulated Lr-AMP1f was 16 µg/mL for E. coli and 32 for S. epidermidis. Nanoencapsulated Lr-AMP1f was nontoxic to HEK293 cells. Promisingly, chitosan NP can be used as a vehicle for the antibacterial application of new AMP (Lr-AMP1f).  aAntibiótico  aPeptídeo  aAtividade antimicrobiana  aCitotoxicidade  aNanocapsulado  aNanotecnologia  aPeptídeo antimicrobiano1 aTAVARES, L. S.1 aFAYER, L.1 aBRANDAO, H. de M.1 aMUNK, M.1 aSANTOS, M. de O.  tArchives of Microbiologygv. 204, n. 3, 184, 2022.